Skip to main content
Top
Published in: CNS Drugs 15/2004

01-12-2004 | Original Research Article

Antidepressant Treatment and Risk of Suicide Attempt by Adolescents with Major Depressive Disorder

A Propensity-Adjusted Retrospective Cohort Study

Authors: Dr Robert J. Valuck, Anne M. Libby, Marion R. Sills, Alexis A. Giese, Richard R. Allen

Published in: CNS Drugs | Issue 15/2004

Login to get access

Abstract

Context: The US FDA has issued an advisory warning of a possible link between antidepressant treatment for paediatric patients with major depressive disorder (MDD) and an increased risk of suicidal behaviour. A large database of paid health insurance claims for adolescents with MDD provided the opportunity to examine this possible relationship.
Objective: To examine the potential empirical link between antidepressant treatment and suicide attempts among adolescents aged 12–18 years using a community sample of managed care enrollees across the US.
Design: A retrospective longitudinal cohort using paid insurance claims for all healthcare and prescription fills for adolescents who were newly diagnosed with MDD and had at least 6 months of follow-up data. A multivariate Cox proportional hazards regression analysis was used to test the hypothesis that antidepressant use increased the risk of suicide attempt, adjusting for propensity for allocation to each treatment group and for demographic and clinical characteristics.
Setting: Managed care plans including both commercial and Medicaid plans in the east, midwest, south and western regions of the US from January 1997 to March 2003.
Participants: All adolescent insurance members aged 12–18 years at first diagnosis of MDD.
Main outcome measures: Suicide attempts as indicated by medical utilisation with International Classification of Diseases (9th edition) [ICD-9] or 10th edition (ICD-10) codes in any healthcare setting or by any covered provider.
Results: 24 119 adolescents met inclusion criteria (63% female). Crude suicide attempt rates ranged from 0.0-2.3% by index treatment group. Treatment with SSRIs (hazard ratio) [HR] = 1.59; CI 0.89, 2.82), other antidepressants (HR = 1.03; CI 0.43, 2.44), or multiple antidepressants (HR = 1.43; CI 0.70, 2.89) after index MDD diagnosis resulted in no statistically increased risk of suicide attempt. Treatment with antidepressant medication for at least 180 days (6 months) reduced the likelihood of suicide attempt compared with antidepressant treatment for <55 days (8 weeks) [HR = 0.34; CI 0.21, 0.55]. Other variables that were independently associated with greater risk of suicide attempts included female gender, severity of illness indicators, younger age at time of MDD diagnosis, and living in the midwest or west.
Conclusions: Antidepressant medication use had no statistically significant effect on the likelihood of suicide attempt in a large cohort of adolescents across the US after propensity adjustment for treatment allocation and controlling for other factors. The relationship between suicidal behaviour and antidepressant medication use is complex and requires further investigation.
Literature
2.
go back to reference Abbott A. British panel bans use of antidepressant to treat children. Nature 2003; 423: 792PubMed Abbott A. British panel bans use of antidepressant to treat children. Nature 2003; 423: 792PubMed
4.
go back to reference Kessler RC, Berglund P, Dernier O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 2003; 289(23): 3095–105PubMedCrossRef Kessler RC, Berglund P, Dernier O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 2003; 289(23): 3095–105PubMedCrossRef
5.
go back to reference Birmaher B, Ryan ND, Williamson D, et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 1996; 35(11): 1427–39CrossRef Birmaher B, Ryan ND, Williamson D, et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 1996; 35(11): 1427–39CrossRef
6.
go back to reference Birmaher B, Arbelaez C, Brent D. Course and outcome of child and adolescent major depressive disorder. Child Adolesc Psychiatr Clin N Am 2002; 11(3): 619–37PubMedCrossRef Birmaher B, Arbelaez C, Brent D. Course and outcome of child and adolescent major depressive disorder. Child Adolesc Psychiatr Clin N Am 2002; 11(3): 619–37PubMedCrossRef
8.
go back to reference Weissman M, Wolk S, Wickramaratne P, et al. Children with prepubertal-onset major depressive disorder and anxiety grown up. Arch Gen Psychiatry. 1999; 56: 794–801PubMedCrossRef Weissman M, Wolk S, Wickramaratne P, et al. Children with prepubertal-onset major depressive disorder and anxiety grown up. Arch Gen Psychiatry. 1999; 56: 794–801PubMedCrossRef
9.
10.
go back to reference Berndt E, Koran L, Finkelstein S, et al. Lost human capital from early-onset chronic depression. Am J Psychiatry 2000; 157: 940–7PubMedCrossRef Berndt E, Koran L, Finkelstein S, et al. Lost human capital from early-onset chronic depression. Am J Psychiatry 2000; 157: 940–7PubMedCrossRef
11.
go back to reference Birmaher B, Brent DA, Benson RS. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 1998; 37(10): 63S–83SCrossRef Birmaher B, Brent DA, Benson RS. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 1998; 37(10): 63S–83SCrossRef
12.
go back to reference Emslie G, Rush A, Weinberg W, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031–7PubMedCrossRef Emslie G, Rush A, Weinberg W, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031–7PubMedCrossRef
13.
go back to reference Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized clinical Trials. JAMA 2003; 290(8): 1033–93PubMedCrossRef Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized clinical Trials. JAMA 2003; 290(8): 1033–93PubMedCrossRef
14.
go back to reference Emslie G, Heiligenstein J, Wagner K, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 1205–15PubMedCrossRef Emslie G, Heiligenstein J, Wagner K, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 1205–15PubMedCrossRef
15.
go back to reference Keller M, Ryan N, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 762–72PubMedCrossRef Keller M, Ryan N, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 762–72PubMedCrossRef
16.
go back to reference Varley C. Psychopharmocological treatment of major depressive disorder in children and adolescents. JAMA 2003; 290(8): 1091–3PubMedCrossRef Varley C. Psychopharmocological treatment of major depressive disorder in children and adolescents. JAMA 2003; 290(8): 1091–3PubMedCrossRef
17.
go back to reference Brent D, Birmaher B. British warning on SSRIs questioned. J Am Acad Child Adolesc Psychiatry 2004; 43(4): 379–80PubMedCrossRef Brent D, Birmaher B. British warning on SSRIs questioned. J Am Acad Child Adolesc Psychiatry 2004; 43(4): 379–80PubMedCrossRef
18.
go back to reference Hazell P, O’Connell D, Heathcote D, et al. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 1995; 310: 897–901PubMedCrossRef Hazell P, O’Connell D, Heathcote D, et al. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 1995; 310: 897–901PubMedCrossRef
19.
go back to reference Shireman T, Olson BM, Dewan NA. Patterns of antidepressant use among children and adolescents. Psychiatr Serv (Chic) 2002; 53(11): 1444–50CrossRef Shireman T, Olson BM, Dewan NA. Patterns of antidepressant use among children and adolescents. Psychiatr Serv (Chic) 2002; 53(11): 1444–50CrossRef
20.
go back to reference McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990; 51 Suppl.: 60–9PubMed McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990; 51 Suppl.: 60–9PubMed
21.
go back to reference McCombs JS, Nichol MB, Stimmel GL. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program. Value Health 1999; 2(4): 269–80PubMedCrossRef McCombs JS, Nichol MB, Stimmel GL. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program. Value Health 1999; 2(4): 269–80PubMedCrossRef
22.
go back to reference Hoagwood K, Burns BJ, Kiser L, et al. Evidence-based practice in child and adolescent mental health services. Psychiatr Serv (Chic) 2001; 52(9): 1179–89CrossRef Hoagwood K, Burns BJ, Kiser L, et al. Evidence-based practice in child and adolescent mental health services. Psychiatr Serv (Chic) 2001; 52(9): 1179–89CrossRef
23.
go back to reference New Freedom Commission on Mental Health. Achieving the promise: transforming mental health care in America. Final report. Rockville, MD: DHHS; 2003. Pub. No. SMA-03-3832 New Freedom Commission on Mental Health. Achieving the promise: transforming mental health care in America. Final report. Rockville, MD: DHHS; 2003. Pub. No. SMA-03-3832
24.
go back to reference Horesh N, Orbach I, Gothelf D, et al. Comparison of the suicidal behavior of adolescent inpatients with borderline personality disorder and major depression. J Nerv Ment Dis 2003; 191(9): 582–8PubMedCrossRef Horesh N, Orbach I, Gothelf D, et al. Comparison of the suicidal behavior of adolescent inpatients with borderline personality disorder and major depression. J Nerv Ment Dis 2003; 191(9): 582–8PubMedCrossRef
25.
go back to reference Zametkin AJ, Atler MR, Yemeni T. Suicide in teenagers: assessment, management, and prevention. JAMA 2001; 286(24): 3120–5PubMedCrossRef Zametkin AJ, Atler MR, Yemeni T. Suicide in teenagers: assessment, management, and prevention. JAMA 2001; 286(24): 3120–5PubMedCrossRef
27.
go back to reference Anderson R. Deaths: leading causes for 2000. National Vital Statistics Report. 2002; 50: 1–85 Anderson R. Deaths: leading causes for 2000. National Vital Statistics Report. 2002; 50: 1–85
28.
go back to reference Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. BMJ 2003; 326: 1–5 Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. BMJ 2003; 326: 1–5
29.
go back to reference Olfson M, Shaffer D, Marcus SC, et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60: 978–82PubMed Olfson M, Shaffer D, Marcus SC, et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60: 978–82PubMed
30.
go back to reference Jick H, Kaye J, Jick S. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292(3): 338–43PubMedCrossRef Jick H, Kaye J, Jick S. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292(3): 338–43PubMedCrossRef
31.
go back to reference Russell M, Taylor D, Cummins G, et al. Use of managed care claims data in the risk assessment of venous thromboembolism in outpatients. Am J Manag Care 2002; 8(1 Suppl.): S3–9PubMed Russell M, Taylor D, Cummins G, et al. Use of managed care claims data in the risk assessment of venous thromboembolism in outpatients. Am J Manag Care 2002; 8(1 Suppl.): S3–9PubMed
32.
go back to reference Valuck R. Treatment of depression with citalopram, fluoxetine, paroxetine, sertraline, and venlafaxine in managed care. Part 1: drug selection, dosing, and utilization. Drug Benefit Trends 2002; 14(7): 23–30 Valuck R. Treatment of depression with citalopram, fluoxetine, paroxetine, sertraline, and venlafaxine in managed care. Part 1: drug selection, dosing, and utilization. Drug Benefit Trends 2002; 14(7): 23–30
33.
go back to reference Valuck R. Treatment of depression with citalopram, fluoxetine, paroxetine, sertraline, and venlafaxine in managed care. Part 2: patient comorbidities and coprescribed therapies. Drug Benefit Trends 2002; 14(8): 33–40 Valuck R. Treatment of depression with citalopram, fluoxetine, paroxetine, sertraline, and venlafaxine in managed care. Part 2: patient comorbidities and coprescribed therapies. Drug Benefit Trends 2002; 14(8): 33–40
34.
go back to reference World Health Organization. ICD-9: international statistical classification of diseases and relation health problems. 9th rev. Geneva: World Health Organization, 1978 World Health Organization. ICD-9: international statistical classification of diseases and relation health problems. 9th rev. Geneva: World Health Organization, 1978
35.
go back to reference World Health Organization. ICD-10: international statistical classification of diseases and relation health problems. 10th rev. Geneva: World Health Organization, 1994 World Health Organization. ICD-10: international statistical classification of diseases and relation health problems. 10th rev. Geneva: World Health Organization, 1994
36.
go back to reference O’Carroll PW, Potter LB. Suicide contagion and the reporting of suicide: recommendations from a national workshop. Morb Mortal Wkly Rep 1994; 43(RR-6): 9–18 O’Carroll PW, Potter LB. Suicide contagion and the reporting of suicide: recommendations from a national workshop. Morb Mortal Wkly Rep 1994; 43(RR-6): 9–18
37.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association, 1994 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association, 1994
38.
go back to reference Martin A, Van Hoof T, Stubbe D, et al. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. Psychiatric Services 2003; 54(1): 72–7PubMedCrossRef Martin A, Van Hoof T, Stubbe D, et al. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. Psychiatric Services 2003; 54(1): 72–7PubMedCrossRef
39.
go back to reference Malone D, Billups S, Valuck R, et al. Development of a chronic disease indicator score using a Veterans Affairs Medical Center medication database. J Clin Epidemiol 1999; 52: 551–7PubMedCrossRef Malone D, Billups S, Valuck R, et al. Development of a chronic disease indicator score using a Veterans Affairs Medical Center medication database. J Clin Epidemiol 1999; 52: 551–7PubMedCrossRef
40.
go back to reference Valuck R, Williams S, MacArthur M, et al. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther 2003; 25: 2936–57PubMedCrossRef Valuck R, Williams S, MacArthur M, et al. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther 2003; 25: 2936–57PubMedCrossRef
41.
go back to reference Rey M, Schulz P, Costa C, et al. Guidelines for the dosage of neuroleptics: I. Chloropromazine equivalents of orally administered neuroleptics. Int Clin Psychiatry 1989; 4: 95–104 Rey M, Schulz P, Costa C, et al. Guidelines for the dosage of neuroleptics: I. Chloropromazine equivalents of orally administered neuroleptics. Int Clin Psychiatry 1989; 4: 95–104
42.
go back to reference Rijcken C, Monster T, Brouwers J, et al. Chlorpromazine equivalents versus defined daily doses: how to compare anti-psychotic drug doses? J Clin Psychopharmacology 2003; 23(6): 657–9CrossRef Rijcken C, Monster T, Brouwers J, et al. Chlorpromazine equivalents versus defined daily doses: how to compare anti-psychotic drug doses? J Clin Psychopharmacology 2003; 23(6): 657–9CrossRef
44.
go back to reference Asburn M, Lipman A. Management of pain in the cancer patient. Anesth Analg 1994; 79(3): 612–4CrossRef Asburn M, Lipman A. Management of pain in the cancer patient. Anesth Analg 1994; 79(3): 612–4CrossRef
45.
go back to reference Steiner J, Prochazka A. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50: 105–16PubMedCrossRef Steiner J, Prochazka A. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50: 105–16PubMedCrossRef
46.
go back to reference Current Procedural Terminology. 4th ed. Chicago (IL): American Medical Association, 2000 Current Procedural Terminology. 4th ed. Chicago (IL): American Medical Association, 2000
47.
go back to reference Wang J, Donnan P. Propensity score methods in drug safety studies: practice, strengths, and limitations. Pharmacoepidemiol Drug Saf 2001; 10: 341–4PubMedCrossRef Wang J, Donnan P. Propensity score methods in drug safety studies: practice, strengths, and limitations. Pharmacoepidemiol Drug Saf 2001; 10: 341–4PubMedCrossRef
48.
go back to reference Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187–202 Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187–202
49.
go back to reference Crown W, Treglia M, Meneades L, et al. Long-term costs of treatment for depression: impact of drug selection and guideline adherence. Value Health 2001; 4(4): 295–307PubMed Crown W, Treglia M, Meneades L, et al. Long-term costs of treatment for depression: impact of drug selection and guideline adherence. Value Health 2001; 4(4): 295–307PubMed
50.
go back to reference SAS Language [computer program]. Version 8.1. Cary (NC): SAS Institute, 2000 SAS Language [computer program]. Version 8.1. Cary (NC): SAS Institute, 2000
51.
go back to reference Wong I, Besag F, Santosh P, et al. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf 2004; 27(13): 991–1000PubMedCrossRef Wong I, Besag F, Santosh P, et al. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf 2004; 27(13): 991–1000PubMedCrossRef
52.
go back to reference Cook TD, Campbell DT. Quasi-experimentation: design and analysis issues for field settings. Chicago (IL): Rand McNally, 1979 Cook TD, Campbell DT. Quasi-experimentation: design and analysis issues for field settings. Chicago (IL): Rand McNally, 1979
53.
go back to reference Vorstman J, Lahuis B, Buitelaar JK. SSRIs associated with behavioral activation and suicidal ideation. J Am Acad Child Adolesc Psychiatry 2001; 40(12): 1364–5PubMedCrossRef Vorstman J, Lahuis B, Buitelaar JK. SSRIs associated with behavioral activation and suicidal ideation. J Am Acad Child Adolesc Psychiatry 2001; 40(12): 1364–5PubMedCrossRef
54.
go back to reference American Psychiatric Association, et al. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157(4): 1–45 American Psychiatric Association, et al. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157(4): 1–45
55.
go back to reference Goldstein B, Goodnick P. Selective serotonin reuptake inhibitors in the treatment of affective disorders: III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998; 12Suppl. B: S57A Goldstein B, Goodnick P. Selective serotonin reuptake inhibitors in the treatment of affective disorders: III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998; 12Suppl. B: S57A
56.
go back to reference Aguglia E, Casacchia M, Cassano G, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993; 8(3): 197–202PubMedCrossRef Aguglia E, Casacchia M, Cassano G, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993; 8(3): 197–202PubMedCrossRef
57.
go back to reference Montgomery SA, Huusom AK. Escitalopram is at least as effective as venlafaxine XR in the treatment of depression and is better tolerated [poster]. 15th Congress of the European College of Neuropsychopharmacology; 2002 Oct 5–9; Barcelona Montgomery SA, Huusom AK. Escitalopram is at least as effective as venlafaxine XR in the treatment of depression and is better tolerated [poster]. 15th Congress of the European College of Neuropsychopharmacology; 2002 Oct 5–9; Barcelona
58.
go back to reference Bielski R, Ventura D, Chang C. A double-blind comparison of escitalopram with venlafaxine XR in the treatment of major depressive disorder [poster]. 16th Congress of the European College of Neuropsychopharmacology; 2003 Sep 20–24; Prague Bielski R, Ventura D, Chang C. A double-blind comparison of escitalopram with venlafaxine XR in the treatment of major depressive disorder [poster]. 16th Congress of the European College of Neuropsychopharmacology; 2003 Sep 20–24; Prague
59.
go back to reference Valuck R. Selective serotonin reuptake inhibitors: a class review. Pharmacy and Therapeutics. 2004; 29(4): 234–43 Valuck R. Selective serotonin reuptake inhibitors: a class review. Pharmacy and Therapeutics. 2004; 29(4): 234–43
60.
go back to reference Schlesselman J. Sample size requirements in cohort and case-control studies of disease. Am J Epidemiol 1974; 99: 381–4PubMed Schlesselman J. Sample size requirements in cohort and case-control studies of disease. Am J Epidemiol 1974; 99: 381–4PubMed
61.
go back to reference Spettell C, Wall T, Allison J, et al. Identifying physician-recognized depression from administrative data: consequences for quality measurement. Health Serv Res 2003; 38(4): 1081–102PubMedCrossRef Spettell C, Wall T, Allison J, et al. Identifying physician-recognized depression from administrative data: consequences for quality measurement. Health Serv Res 2003; 38(4): 1081–102PubMedCrossRef
62.
go back to reference Rost K, Smith R, Matthews D, et al. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med 1994; 3(4): 333–7PubMedCrossRef Rost K, Smith R, Matthews D, et al. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med 1994; 3(4): 333–7PubMedCrossRef
63.
go back to reference Hirschfeld R, Keller M, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997; 277(4): 333–40PubMedCrossRef Hirschfeld R, Keller M, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997; 277(4): 333–40PubMedCrossRef
64.
go back to reference Lemelin J, Hotz S, Swensen R, et al. Depression in primary care: why do we miss the diagnosis? Can Fam Physician 1994; 40: 104–8PubMed Lemelin J, Hotz S, Swensen R, et al. Depression in primary care: why do we miss the diagnosis? Can Fam Physician 1994; 40: 104–8PubMed
Metadata
Title
Antidepressant Treatment and Risk of Suicide Attempt by Adolescents with Major Depressive Disorder
A Propensity-Adjusted Retrospective Cohort Study
Authors
Dr Robert J. Valuck
Anne M. Libby
Marion R. Sills
Alexis A. Giese
Richard R. Allen
Publication date
01-12-2004
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 15/2004
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200418150-00006

Other articles of this Issue 15/2004

CNS Drugs 15/2004 Go to the issue

Acknowledgments

Acknowledgement

Review Article

Remifentanil Update